15 stories mentioning ZTS
Every FINWIRES story that references ZTS, newest first.
Zoetis (ZTS) has an average rating of overweight and mean price target of $123.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.
Healthcare stocks were lower late Monday afternoon with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas lowered the company's price target to $146 from $185, following the company's Q1 results late last week.
HSBC downgraded Trade Desk (TTD) to reduce from hold while adjusting its price target to $20 from $31.Shares of Trade Desk were down 7.2%, with intraday trading volume at more than 12.6 million, compared with the stock's daily average of about 20.8 million.BNP Paribas adjusted the price target for Zoetis (ZTS) shares to $146 from $185, following the company's Q1 results late last week.Shares of Zoetis dropped 7.5%, with intraday trading volume at over 7.94 million, compared with a daily average of about 4.61 million.Certara (CERT) reported Q1 adjusted earnings below market expectations on Monday, while sales rose moderately from a year ago.Shares slumped 20% as intraday trading volume catapulted to more than 3.99 million from a daily average of about 3.67 million.Price: $21.33, Change: $-1.73, Percent Change: -7.50%
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each shedding about 0.9%. The iShares Biotechnology ETF (IBB) decreased 0.3%.In sector news, President Donald Trump has approved a plan to fire the US Food and Drug Administration Commissioner Marty Makary, the Wall Street Journal reported Friday. Trump expressed displeasure in recent days with Makary for taking too long to approve flavored vapes and nicotine pouches, the Journal reported earlier this week.In corporate news, Zoetis (ZTS) shares fell past 5% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS also cut its price target to $99 from $130, and Jefferies to $117 from $155.Traws Pharma (TRAW) shares surged 28%. The company said Friday it plans to develop potential therapies for the treatment and prevention of hantavirus infections using its portfolio of antiviral drug candidates targeting negative-strand RNA viruses.Novo Nordisk (NVO) saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg reported, citing data from market researcher Pharmarack. Novo added 0.5%.PTC Therapeutics (PTCT) shares jumped past 14% after posting a smaller-than-expected net loss for Q1, as well as total revenue that surpassed analysts' consensus.
Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) was 0.4% higher.In corporate news, Zoetis (ZTS) shares fell past 6% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS cut the company's price target to $99 from $130, and Jefferies to $117 from $155.Traws Pharma (TRAW) shares surged 24%. The company said Friday it plans to develop potential therapies for the treatment and prevention of hantavirus infections using its portfolio of antiviral drug candidates targeting negative-strand RNA viruses.Novo Nordisk (NVO) saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg reported, citing data from market researcher Pharmarack. Novo added 0.2%.
Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) was 0.4% higher.In corporate news, Zoetis (ZTS) shares fell 6% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS cut its price target to $99 from $130, and Jefferies to $117 from $155.
Zoetis (ZTS) has an average rating of overweight and mean price target of $135, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $84.11, Change: $-3.20, Percent Change: -3.67%
Zoetis (ZTS) has an average rating of overweight and mean price target of $135, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $83.81, Change: $-3.50, Percent Change: -4.01%
Zoetis (ZTS) has an average rating of overweight and mean price target of $135, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $84.16, Change: $-3.15, Percent Change: -3.61%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $96 from $150, 12.9x our 2027 EPS estimate, a discount to ZTS's 10-year historical forward P/E average. We cut our 2026 EPS view to $6.92 from $7.03. We keep our 2027 EPS forecast at $7.43. Shares of ZTS are down more than 21% today after the company missed estimates, recording flat organic growth Y/Y, while guidance for the full 2026 for both revenue ($9.680B-$9.960B, 2%-5% organic operational growth) and adjusted EPS ($6.85-$7.00) was cut above expectations, which, in our view, signals that the challenging first quarter environment is likely to persist. The Q1 performance showed significant segment divergence: International business grew 10% organically, while the U.S. segment declined 8%. The Livestock division showed robust 12% organic growth, contrasting with a 4% operational decline in Companion Animal. The U.S. segment saw an 8% revenue decline, with companion animal down 11% due to pet owner price sensitivity, aggressive competitor pricing, and lack of market expansion.
US equity indexes ended lower on Thursday amid conflicting signals from the US on the war with Iran, triggering renewed concerns that the conflict will drag on.* Iran has created a government agency to vet and tax vessels seeking passage through the Strait of Hormuz, the Associated Press reported, citing Lloyd's List Intelligence. Tehran is reviewing the latest US proposals for ending the war.* US initial jobless claims last week rose to 200,000 from an upwardly revised 190,000 in the previous week, compared with expectations for 205,000 in a survey of analysts compiled by Bloomberg.* June West Texas Intermediate crude oil rose $1.28 to settle at $96.36 per barrel, while July Brent crude, the global benchmark, was last seen up $0.61 at $101.88.* Zoetis (ZTS) shares fell 22%, the steepest decline on the S&P 500, after the company reported Q1 adjusted earnings and revenue below market expectations and scaled back full-year guidance.* Datadog (DDOG) shares rose 31%, the biggest gain on the S&P, after the company raised its full-year outlook and posted Q1 results that topped Wall Street expectations.
Planet Fitness (PLNT) shares tumbled 32% after the company Thursday tempered its full-year outlook amid fewer-than-expected member additions in Q1.More than 12.7 million shares of the company traded intraday compared with a daily average of about 1.8 million.Zoetis (ZTS) reported Q1 adjusted earnings and revenue Thursday below market expectations, while scaling back its full-year 2026 guidance.Shares sank 20% following a surge in intraday trading volume to over 22.4 million from a daily average of about 4 million.ARM (ARM) Chief Executive Rene Haas said, in an earnings call with investors, that while demand for ARM's new AGI CPU doubled to $2 billion within six weeks of its launch, the company has only secured enough manufacturing capacity to fulfill half of those orders.Shares dropped 10%, with intraday trading volume at over 18.9 million versus a daily average of about 7.4 million.Price: $43.38, Change: $-20.59, Percent Change: -32.18%
The Dow Jones Industrial Average was down, while the S&P 500 Index and the Nasdaq Composite were up in late-morning trading Thursday, as oil prices fell below $100 on hopes that the US and Iran are nearing an agreement to end their war.In company news, Citigroup (C) Chief Executive Jane Fraser said Thursday at the bank's Investor Day that Citi expects its return on tangible common equity to hit a range of 11% to 13% in 2027 and 2028, up from 10% to 11% currently, before rising further to 14% to 15% from 2029 to 2031, according to a slide deck the company published. Citigroup shares were up 2.1% around midday.Datadog (DDOG) reported Q1 non-GAAP net income Thursday of $0.60 per diluted share, up from $0.46 a year earlier and above the FactSet consensus of $0.51. First-quarter revenue was $1.01 billion, up from $761.6 million a year ago and above the FactSet consensus of $960.1 million. For Q2, the company said it expects non-GAAP EPS of $0.57 to $0.59 on revenue of $1.07 billion to $1.08 billion. Analysts polled by FactSet expect $0.50 and $994 million, respectively. For full-year 2026, Datadog said it expects non-GAAP EPS of $2.36 to $2.44 on revenue of $4.30 billion to $4.34 billion, up from the previous guidance ranges of $2.08 to $2.16, and $4.06 billion to $4.12 billion, respectively. Analysts polled by FactSet expect earnings of $2.16. Datadog shares were up 29.6%.McDonald's (MCD) reported Q1 adjusted earnings Thursday of $2.83 per diluted share, up from $2.67 a year earlier and above the FactSet consensus of $2.74. First-quarter revenue was $6.52 billion, up from $5.96 billion a year ago and above the FactSet consensus of $6.47 billion. McDonald's shares were down 0.4%.Zoetis (ZTS) reported Q1 adjusted earnings Thursday of $1.53 per diluted share, up from $1.41 a year earlier but below the FactSet consensus of $1.60. First-quarter revenue was $2.26 billion, up from $2.20 billion a year ago but below the FactSet consensus of $2.30 billion. For full-year 2026, the company said it expects adjusted EPS of $6.85 to $7.00, down from its previous guidance of $7.00 to $7.10 and below the FactSet consensus of $7.03. The company also lowered its full-year 2026 revenue guidance to $9.68 billion to $9.96 billion from $9.83 billion to $10.03 billion previously. Analysts polled by FactSet expect $9.89 billion. Zoetis shares were down 22%.Arm (ARM) reported fiscal Q4 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.55 a year earlier and above the FactSet consensus of $0.58. Fiscal Q4 revenue was $1.49 billion, up from $1.24 billion a year ago and above the FactSet consensus of $1.47 billion. For fiscal Q1, the company said it expects adjusted EPS of $0.40, plus or minus $0.04, on revenue of $1.26 billion, plus or minus $50 million. Analysts polled by FactSet expect $0.37 and $1.25 billion, respectively. Arm shares were down 8.4%.Whirlpool (WHR) reported a Q1 adjusted loss late Wednesday of $0.56 per diluted share, swinging from adjusted earnings of $1.70 a year earlier and compared with the FactSet consensus of earnings of $0.38. First-quarter revenue was $3.27 billion, down from $3.62 billion a year ago and below the FactSet consensus of $3.44 billion. For fiscal 2026, the company said it expects adjusted EPS of $3 to $3.50, down from its previous guidance of $7 and below the FactSet consensus of $4.83. Full-year revenue is expected to be about $15 billion, down from its prior guidance of $15.30 billion to $15.60 billion and below the FactSet consensus of $15.26 billion. The company said the war in Iran has triggered a "recession-level industry decline in the US." Whirlpool shares were down 12.3%.Shake Shack (SHAK) reported breakeven fiscal Q1 adjusted earnings Thursday, compared with $0.14 per diluted share a year earlier and below the FactSet consensus of $0.12. Fiscal Q1 revenue was $366.7 million, up from $320.9 million a year ago but below the FactSet consensus of $372.4 million. Shake Shack also said it has appointed Michelle Hook as chief financial officer, effective May 11. Shares of the company were down 28.6%.Price: $130.33, Change: $+2.72, Percent Change: +2.14%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ZTS delivered challenging Q1 2026 results with adjusted EPS of $1.53 (+9% Y/Y) missing the consensus view of $1.62, while revenue of $2.262B (+3% Y/Y) met expectations. Performance reflected divergent regional dynamics, with International segment growth of 17% Y/Y ($1.149B) offsetting an 8% Y/Y decline in the U.S. segment ($1.090B). The company faced intensified competitive pressure in key dermatology franchises and heightened macroeconomic headwinds affecting U.S. pet owners, leading to reduced veterinary visits and softer demand for premium products. Management revised full-year 2026 guidance to $9.680B-$9.960B for revenue (2%-5% organic operational growth) and adjusted EPS of $6.85-$7.00, acknowledging current market pressures. We believe ZTS could be well-positioned for long-term growth with its portfolio breadth, robust pipeline of potential blockbusters, and proven innovation capabilities as key competitive advantages if it successfully navigates near-term headwinds.